Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:CMHC -2.89%81 3-Year Book Growth Rate is 0.10% as of Jun. 2026, which is 98% below its 10-year median of 6.30. GuruFocus rates XSWX:CMHC with a GF Score™ of 81/100 and a GF Value™ of CHF40.77 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 909 Drug Manufacturers companies, Cosmo NV ranks worse than 66.89% on this metric.
During the past 12 months, Cosmo NV's average Book Value per Share Growth Rate was 12.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 0.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -2.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Cosmo NV was 132.10% per year. The lowest was -8.00% per year. And the median was 6.30% per year.
Cosmo NV (XSWX:CMHC) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Cosmo NV 3-Year Book Growth Rate Related Terms
XSWX:CMHC vs LLY, JNJ, ABBV: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Cosmo NV's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 0.10% mean?
Cosmo NV (XSWX:CMHC) has a 3-Year Book Growth Rate of 0.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cosmo NV and its competitors. This is 98% below median its historical median of 6.30. According to the industry distribution chart, Cosmo NV ranks #608 out of 909 companies in the Drug Manufacturers industry, placing it in the top 66.9%.
Is Cosmo NV's 3-Year Book Growth Rate too high?
Cosmo NV's current 3-Year Book Growth Rate of 0.10% is 98% below median its 10-year median of 6.30. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.70. Cosmo NV's value of 0.10% is 97.9% below this industry median. Based on the distribution chart, Cosmo NV ranks #608 out of 909 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cosmo NV has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's 3-Year Book Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #608 out of 909 companies for 3-Year Book Growth Rate. This places Cosmo NV in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.70. Cosmo NV's value of 0.10% is 97.9% below this benchmark. While the company's 10-year median is 6.30 vs. the industry median of 4.70, Cosmo NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.70, based on 909 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current 3-Year Book Growth Rate of 0.10% is 97.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cosmo NV and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current 3-Year Book Growth Rate is 0.10%, which is 98% below median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:CMHC) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.77, compared to a current price of CHF57.10 — trading 40.1% above its estimated fair value. The current 3-Year Book Growth Rate is 0.10%, which is 98% below median its 10-year median of 6.30 and 97.9% below the Drug Manufacturers industry median of 4.70. Cosmo NV's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Cosmo NV (XSWX:CMHC), the current 3-Year Book Growth Rate is 0.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:CMHC) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF57.10 is trading 40.1% above its estimated GF Value™ of CHF40.77.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:CMHC:
3-Year Book Growth Rate: 0.10% (98% below median its 10-year median of 6.30)
GF Value™: CHF40.77 vs. price of CHF57.10 (40.1% above fair value)
Industry Position: 97.9% below the Drug Manufacturers median (#608 of 909)
No single metric tells the full story. See the XSWX:CMHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
81GF Score
Get the complete analysis for XSWX:CMHC
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CMHC has been successfully added to your 
